The Newest CGMs for Type 1 Diabetes: Upcoming Glucose Sensors, Features & Age Guide (2026 Update)

Continuous glucose monitoring (CGM) has transformed life with Type 1 Diabetes and the next generation of sensors promises longer wear, greater accuracy, multi-analyte tracking, and more seamless integration with automated insulin delivery (AID) systems. From year long implantables to needle free sensors, here’s what’s coming next.

1. Eversense 365- The First 365 Day Implantable CGM

The Eversense 365 is the world’s first one year implantable CGM, approved by the FDA in 2024 and now expanding into Europe. It requires only one insertion per year, eliminating the frequent sensor changes typical of 10-14 day wear CGM. Suitable for those age 18 or older.

Key features include:

• 365 day wear time

• High accuracy with minimal false alerts

• Removable transmitter with vibration alerts

• No risk of knocking off the sensor

2. Libre Duo- Abbott’s Dual Glucose/ Ketone Sensor

Abbott is developing a dual-analyte sensor, Libre Duo, that measures glucose and ketones simultaneously, a potentially game changing tool for people with Type 1 Diabetes who face the risk of diabetic ketoacidosis (DKA).

Key features include:

• Built on the Libre 3 Plus form factor

• Designed for integration with multiple AID systems

• Expected market arrival as early as next year

3. Medtronic Simplera CGM- Smaller, Integrated, and Expanding

The Medtronic Simplera is part of Medtronic’s next generation smart system, including:

• Integration with the upcoming MiniMed 8 series pump

• Planned compatibility with Abbott Libre sensors

• A push toward more flexible AID options

4. Dexcom G7 and the Next Generation (G8 & Beyond)

The Dexcom G7 remains one of the most widely used CGMs, with:

• A 60% smaller footprint than the G6

• A 27 minute warm up

• Improved accuracy

Dexcom is also working on:

• G8 development

• Expanded AID integrations

• Direct to watch connectivity

5. Abbott FreeStyle Libre 3 & Libre Rio

Abbott’s Libre line continues to evolve:

• Libre 3: real time minute-by-minute glucose updates

• Libre Rio: OTC CGM for adults with Type 2 Diabetes

• Improved app and EHR integration

6. Biolinq Shine- The First Needle Free CGM

The Biolinq Shine is the first FDA cleared needle free glucose biosensor.

What makes it different?

• No insertion needle

• No filament under the skin

• Uses a microsensor array

• Tracks glucose plus activity and sleep data

7. Eversense E3- Six Month Implantable CGM

The Eversense E3 offers:

• 180 day wear

• Twice yearly insertion

• High accuracy

• 1-2 calibrations per day

8. Additional Emerging Technologies to Watch

These devices are not all CGMs, but they shape the future of diabetic systems for Type 1 Diabetes:

• Sequel’s twiist AID system

• Modular Medical’s MODD1 patch pump

• Tandem Mobi pump

• Omnipod 5 expansions

What These New Sensors Mean for Your Family

Managing Type 1 Diabetes as a parent is a constant balance: keeping your child safe, helping them feel confident and independent, and trying not to spend every waking moment thinking about glucose numbers. The good news is that the next generation of CGMs is being designed with exactly these pressures in mind.

Longer Lasting Sensors = Fewer Insertions, Less Stress

New implantable sensors like the Eversense 365 last a full year, meaning:

• No more changing sensors every 10-14 days

• No more worrying about sensors falling off during sports, festivals, travelling or everyday life

Glucose and Ketones in One Sensor

Abbott’s upcoming dual sensor checks glucose and ketones at the same time, offering:

• Faster warning signs during illness

• Earlier detection of pump issues

• Less guesswork when your child “just doesn’t seem right”

Smaller, Quieter, More Discreet Sensors

Newer CGMs- Dexcom G7, Libre 3, Simplera- are:

• Smaller

• Faster to warm up

• Better at filtering false alarms

• Easier to hide under clothes

Better Integration with Pumps and AID Systems

Most upcoming sensors are being designed to work with more pumps and AID systems, meaning:

• More choice

• More flexibility

• More time in range with less manual correction

Needle Free Options Are Coming

The Biolinq Shine uses tiny micro sensors instead of a needle, a promising option for:

• Children with sensory sensitivities

• Kids who fear insertions

• Families who struggle with site rotation

Where to Learn More

Readers can explore more through:

• Senseonics updates on Eversense 365 and E3

• Abbott’s dual glucose ketone sensor announcements

• Medtronic Simplera and MiniMed ecosystem updates

• Dexcom G7 and G8 development news

• Biolinq Shine FDA clearance

Final Thoughts

The next wave of CGM technology is moving toward devices that are smaller, smarter, longer lasting, and far more intuitive. Whether it’s year long implantables, needle free sensors, or dual glucose ketone monitoring, the direction is clear: less burden, more safety, and more freedom for people living with Type 1 Diabetes, and for the families who support them. As these innovations continue to roll out, they offer something truly meaningful: the chance to spend less time managing diabetes and more time simply living life.